MASP2: Mannan-binding lectin serine protease 2
Precursor of a serum protease that activates the lectin pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on MASP2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Narsoplimab | Phase 3 | Omeros | Antibody | InhibitorMannan-binding lectin serine protease 2 inhibitor | 3 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.| Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT) | Narsoplimab | — | Not yet recruiting | Manuel Ricardo Espinoza-Gutarra | Feb 2, 2026 |
| Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA | Narsoplimab | Phase 2 | Recruiting | Omeros Corporation | May 11, 2023 |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | Narsoplimab | Phase 2 | Active, not recruiting | QuantumLeap Healthcare Collaborative | Jul 27, 2020 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Immunodeficiency due to MASP-2 deficiency
- 0.69
- Frontotemporal dementia with motor neuron disease
- 0.57
- Motor neuron disorder
- 0.44
- Abnormality of the skeletal system
- 0.41
- COVID-19
- 0.40
- Complement deficiency
- 0.37
- Increased total eosinophil count
- 0.34
- Atypical hemolytic-uremic syndrome
- 0.33
- Neurodegenerative disease
- 0.29
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4295646, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt O00187, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets